Moderna Inc (MRNA) Stock Price, Quote & News

Company Profile

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseas...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 714 6500

Website: www.modernatx.com

Address:

325 Binney Street, Cambridge, United States

IndyOne Jul. 4 at 5:16 PM

$MRNA Trade what you see, 1 month chart for Moderna. Buy, Buy some more. HOLD. A lot of people sold $NVDA after a double in the early days. Regret. From the bottom, NVIDIA is up 6,494 x. A $1,000 investment in NVIDIA at the bottom is now worth $6,494,333. Unfortunately NVIDIA may now have "big company disease". The NVIDIA market cap is $4.7 trillion. USA GDP is $31.9 trillion - the run is done? Moderna market cap is only $31 billion. Plenty of runway left, for instance, $LLY is $1.1 trillion. Moderna's Cancer, Respiratory, and Rare Disease empire forming now. This new franchise and platform could hold a 35 times your investment from here. Some say mRNA is as big as GLPs. Diversify into Moderna.

0 · Reply

Biotechlineup Jul. 4 at 4:35 PM

$MRNA mRNA-4157 is a highly impressive clinical tool that halves melanoma recurrence in controlled clinical environments, but it is an operational and financial nightmare to commercialize. Moderna's Albatross. The Multi-Billion Dollar Pipeline DragFor Moderna, its sprawling pipeline of 40+ active mRNA candidates has transformed from its greatest selling point into a massive corporate albatross.Funding Phase 3 global field trials across oncology, rare diseases, and seasonal respiratory combinations requires immense capital. Cash Drain, With COVID-19 revenues cratering and its RSV entry struggling in a distant third place, Moderna is burning through $2.5 Billion to $3.0 Billion a year out of pocket just to support this pipeline infrastructure with mostly guaranteed failures. Moderna is weighed down by an increasingly expensive, capital-intensive pipeline that will carry very low long-term commercial profit. Yes in a short squeeze and technical uptrend for sure.Long term the inevitable

0 · Reply

IndyOne Jul. 4 at 4:18 PM

$MRNA Trade what you see. Short squeeze has just begun, whoever shorted 58 million shares will be wrecked. New cancer franchise - billions. V940!!! Moderna’s individualized mRNA‑4157 (V940) cancer vaccine is the most advanced immunotherapy platform ever built. It identifies a patient’s unique tumor mutations, designs a custom mRNA construct, and trains the immune system to target the exact neoantigens driving the disease. The result: reduced recurrence and death by ~50% in melanoma. Applies also to non‑small cell lung cancer, bladder cancer, renal cell cancer, and more. AI‑driven neoantigen selection, rapid mRNA design, and scalable lipid‑nanoparticle delivery create a speed in supply chain and manufacturing. Every improvement in sequencing speed, manufacturing automation, and bioinformatics compounds across the entire oncology pipeline. Moderna tuning processes for speed including V940, flu, and admin. If you have these skills, APPLY TO THESE MODERNA AUTOMATION JOBS TODAY!

1 · Reply

Biotechlineup Jul. 4 at 1:40 PM

$MRNA Moderna 4157 individualized vaccine that sequences a specific tumor and prints a custom mRNA strand in a sterile lab is a breathtaking, noble scientific achievement. However, the requirement of a 60 day manufacturing delay, astronomical per patient production costs of hundreds of thousands , severe logistical bottlenecks and Insurance reimbursement unlikely turn it into an ephemeral innovation. Moderna burns through billions of dollars trying to scale this highly complex process, the rest of oncology is leapfrogging them with off-the-shelf therapies. Platforms like Matrix-M adjuvanted proteins or advanced multi-specific antibodies aim to recruit the immune system universally and instantly, without needing a custom, multi-week manufacturing loop. Moderna has built a highly complex, expensive solution for a problem that cheaper, faster, and more practical biotechnology is quickly leapfrogging. Classic "Leapfrog Casualty." brilliant, highly sophisticated idea fails commercially.

0 · Reply

BioTechHealthX Jul. 4 at 12:45 PM

$ALNY $AMGN $BNTX $GILD $MRNA From GLP-1 obesity drugs to mRNA cancer therapies and rare disease treatments, these 10 biotech and biopharma stocks are linked to some of the strongest innovation trends reshaping medicine and Wall Street. https://biotechhealthx.com/biotech-news/10-biotech-stocks-that-could-turn-medicine-into-wall-streets-next-gold-rush/

0 · Reply

TomMac64 Jul. 4 at 10:29 AM

$JNJ $LLY $MRNA $VNDA Doesn’t have to be at $30 + what’s wrong with $15 + the OS float is 60M that’s after 20 years public …. AMAZING !

0 · Reply

fastengels Jul. 4 at 10:07 AM

$MRNA This is just the beginning for Moderna. Now it’s really taking off.

0 · Reply

TradeForLifeKing Jul. 4 at 5:58 AM

$MRNA company should buy instantly $ADTX company that has amazing pipeline everyone for at minimum $10-$20 per share all deal!!!

1 · Reply

Investor203 Jul. 4 at 5:39 AM

$MRNA who is buying $VNDA at $30+? $JNJ $LLY or someone else

0 · Reply

IndyOne Jul. 4 at 4:39 AM

$MRNA V940 news coming

0 · Reply

Moderna stock jumps as pipeline progress and flu shot data lift sentiment

Jul 1, 2026, 6:50 PM EDT - 2 days ago

Jim Cramer says this former Covid market darling is finally investable again

Jun 30, 2026, 7:34 AM EDT - 4 days ago

The 20 best-performing stocks in the S&P 500 for the first half of 2026

AMD CIEN COHR DELL FIX FLEX GLW

Jun 26, 2026, 2:47 PM EDT - 7 days ago

Moderna stock soars as cancer pipeline and CAR-T push ignite optimism

Jun 26, 2026, 2:39 PM EDT - 7 days ago

Healthcare stocks have become a haven for investors ditching tech

ABBV ABSI APGE JNJ LLY SNY XBI

2026-06-26T18:37:26.000Z - 7 days ago

Why Moderna (MRNA) Stock Is Soaring Today – June 26, 2026

2026-06-26T16:00:14.000Z - 8 days ago

Moderna rises 14.2%

Jun 26, 2026, 11:36 AM EDT - 8 days ago

Why Moderna Stock Is Soaring and Leading the S&P 500 Today

2026-06-26T14:07:30.000Z - 8 days ago

Moderna rises 8.7%

2026-06-26T13:25:28.000Z - 8 days ago

Moderna price target raised to $77 from $69 at Piper Sandler

Jun 25, 2026, 9:00 AM EDT - 9 days ago

Moderna Transcript: Science Day 2026

Jun 25, 2026, 9:00 AM EDT - 9 days ago

Moderna Slides: FY 2026

2026-06-25T11:11:06.000Z - 9 days ago

Moderna Science Day highlights potential of mRNA platform

Jun 25, 2026, 7:00 AM EDT - 9 days ago

Moderna Science Day Highlights Expanding Potential of mRNA Platform

Jun 18, 2026, 4:23 PM EDT - 15 days ago

FDA Votes in Favor of Benefit-Risk Profile for Moderna's Flu Vaccine

2026-06-18T20:05:10.000Z - 15 days ago

Moderna announces FDA advisory committee votes in favor of mRNA-1010

2026-06-18T20:01:28.000Z - 15 days ago

Moderna up 4% after FDA advisers back flu vaccine approval

Jun 18, 2026, 4:00 PM EDT - 15 days ago

Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine

2026-06-18T19:40:11.000Z - 15 days ago

Jefferies’ confidence in Moderna’s mRNA flu shot rises after AdCom support

Jun 18, 2026, 2:48 PM EDT - 15 days ago

US FDA advisers vote in favor of Moderna's flu vaccine

2026-06-18T18:45:10.000Z - 15 days ago

FDA panel backs Moderna mRNA-based influenza vaccine, Bloomberg reports

Jun 18, 2026, 6:01 AM EDT - 16 days ago

Moderna's mRNA flu vaccine faces FDA advisory panel scrutiny

Jun 17, 2026, 7:00 AM EDT - 17 days ago

Moderna to Host Investor Event - Science Day

Jun 17, 2026, 2:38 AM EDT - 17 days ago

Moderna interested in Germany production, sees opportunity in BioNTech closures, says CEO

BNTX

2026-06-16T16:05:26.000Z - 18 days ago

BofA says VRBPAC docs look supportive but keeps Moderna at Underperform

2026-06-16T13:24:19.000Z - 18 days ago

FDA posts briefing docs for meeting to discuss Moderna influenza vaccine

2026-06-16T13:21:09.000Z - 18 days ago

Moderna flu vaccine briefing docs ‘read favorably,’ says Jefferies

Jun 16, 2026, 9:12 AM EDT - 18 days ago

US FDA staff says data may support effectiveness of Moderna's flu vaccine in older adults

Jun 16, 2026, 8:37 AM EDT - 18 days ago

Moderna announces executive changes ahead of potential launches

2026-06-16T11:40:13.000Z - 18 days ago

Moderna president Stephen Hoge to assume expanded role, Ester Banque named CCO

ZTS

Jun 16, 2026, 7:30 AM EDT - 18 days ago

Moderna Announces Organizational Changes to Prepare for Multiple Product Launches in 2027 and 2028

Jun 9, 2026, 3:20 PM EDT - 24 days ago

Moderna Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 7:01 PM EDT - 25 days ago

Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome

2026-06-08T10:52:26.000Z - 26 days ago

Moderna price target raised to $34 from $32 at BofA

Jun 3, 2026, 8:10 AM EDT - 4 weeks ago

Wall Street hated these 15 stocks. Then their earnings proved the analysts wrong.

AES ARW BAX EXP EXPD HPQ IESC

Jun 2, 2026, 4:34 PM EDT - 4 weeks ago

Moderna Launches Moderna Direct with “eCommerce Powered by FFF Enterprises™”

Jun 2, 2026, 7:00 AM EDT - 4 weeks ago

Moderna to Present at Upcoming Conference in June 2026

Jun 1, 2026, 7:15 PM EDT - 4 weeks ago

Moderna Transcript: Study update

Jun 1, 2026, 7:15 PM EDT - 4 weeks ago

Moderna Press release: Study update

Jun 1, 2026, 7:15 PM EDT - 4 weeks ago

Moderna Slides: Study update

Jun 1, 2026, 8:00 AM EDT - 4 weeks ago

Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting

MRK

Jun 1, 2026, 5:37 AM EDT - 4 weeks ago

Moderna partners with global health coalition to develop Bundibugyo Ebola vaccine

Jun 1, 2026, 5:00 AM EDT - 4 weeks ago

Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus

May 28, 2026, 10:00 AM EDT - 5 weeks ago

Moderna Transcript: Bernstein 42nd Annual Strategic Decisions Conference

May 21, 2026, 5:03 PM EDT - 6 weeks ago

Moderna, Merck cancer combo cuts melanoma spread risk at five years

MRK

May 21, 2026, 11:26 AM EDT - 6 weeks ago

US FDA to hold expert committee meeting to review Moderna's flu vaccine

May 19, 2026, 10:00 AM EDT - 6 weeks ago

Moderna Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 12, 2026, 5:00 PM EDT - 7 weeks ago

Moderna Recognized by TIME as One of the World's Most Impactful Companies

May 12, 2026, 2:20 PM EDT - 7 weeks ago

Moderna Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 1:25 PM EDT - 7 weeks ago

Moderna's AI Could Get a Hantavirus Vaccine Here Faster

May 11, 2026, 11:44 PM EDT - 7 weeks ago

Hantavirus outbreak: these 3 stocks are poised to rip higher

MMM QDEL

May 11, 2026, 8:19 PM EDT - 7 weeks ago

Moderna Says It's Researching a Hantavirus Vaccine. The Drugmaker's Stock Is Surging.

May 11, 2026, 1:17 PM EDT - 7 weeks ago

Here's how much Moderna's stock has rallied off renewed focus on hantavirus research

May 11, 2026, 10:44 AM EDT - 7 weeks ago

Moderna stock soars as hantavirus fears spark outbreak trade

May 11, 2026, 7:53 AM EDT - 7 weeks ago

Hantavirus cases spark surge in pharma and biotech stocks — here's why

EBS INO NVAX

May 11, 2026, 5:29 AM EDT - 7 weeks ago

Moderna Stock Jumps. U.S. Passenger on Hantavirus Cruise Ship Tests Positive.

May 8, 2026, 2:44 PM EDT - 2 months ago

How Hantavirus Made Moderna a Must-Own Stock Again

May 6, 2026, 5:15 PM EDT - 2 months ago

Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010

May 6, 2026, 5:01 PM EDT - 2 months ago

Moderna's mRNA flu vaccine outperforms standard shot in late-stage trial

May 6, 2026, 8:00 AM EDT - 2 months ago

Moderna Transcript: AGM 2026

May 1, 2026, 8:00 AM EDT - 2 months ago

Moderna Earnings Call Transcript: Q1 2026

May 1, 2026, 8:00 AM EDT - 2 months ago

Moderna Slides: Q1 2026

May 1, 2026, 8:00 AM EDT - 2 months ago

Moderna Quarterly report: Q1 2026

May 1, 2026, 8:00 AM EDT - 2 months ago

Moderna Earnings release: Q1 2026

May 1, 2026, 7:46 AM EDT - 2 months ago

Moderna Stock Spikes After Earnings. Covid Vaccine Revenue Is a Growth Driver Again.

May 1, 2026, 6:37 AM EDT - 2 months ago

Moderna Reports Higher Revenue but Posts a Loss

May 1, 2026, 6:32 AM EDT - 2 months ago

Moderna tops quarterly revenue estimates on stronger international COVID vaccine sales

May 1, 2026, 6:30 AM EDT - 2 months ago

Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates

Apr 24, 2026, 4:52 PM EDT - 2 months ago

CureVac sues Moderna for patent infringement over COVID-19 vaccines

CVAC

Apr 21, 2026, 7:13 PM EDT - 2 months ago

Moderna starts late-stage trial of bird flu vaccine in US, UK

Apr 21, 2026, 7:01 PM EDT - 2 months ago

Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate

Apr 21, 2026, 10:00 AM EDT - 2 months ago

Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting

Apr 21, 2026, 9:59 AM EDT - 2 months ago

Moderna wins EU approval for combined flu, COVID shot for older adults

Apr 21, 2026, 9:40 AM EDT - 2 months ago

Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19

Apr 21, 2026, 7:00 AM EDT - 2 months ago

Moderna to Present at Upcoming Conferences in May 2026

Apr 17, 2026, 3:00 PM EDT - 2 months ago

Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting

Apr 15, 2026, 7:00 AM EDT - 2 months ago

Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026

Apr 6, 2026, 6:01 PM EDT - 3 months ago

Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026

IndyOne Jul. 4 at 5:16 PM

0 · Reply

Biotechlineup Jul. 4 at 4:35 PM

0 · Reply

IndyOne Jul. 4 at 4:18 PM

1 · Reply

Biotechlineup Jul. 4 at 1:40 PM

0 · Reply

BioTechHealthX Jul. 4 at 12:45 PM

0 · Reply

TomMac64 Jul. 4 at 10:29 AM

$JNJ $LLY $MRNA $VNDA Doesn’t have to be at $30 + what’s wrong with $15 + the OS float is 60M that’s after 20 years public …. AMAZING !

0 · Reply

fastengels Jul. 4 at 10:07 AM

$MRNA This is just the beginning for Moderna. Now it’s really taking off.

0 · Reply

TradeForLifeKing Jul. 4 at 5:58 AM

$MRNA company should buy instantly $ADTX company that has amazing pipeline everyone for at minimum $10-$20 per share all deal!!!

1 · Reply

Investor203 Jul. 4 at 5:39 AM

$MRNA who is buying $VNDA at $30+? $JNJ $LLY or someone else

0 · Reply

IndyOne Jul. 4 at 4:39 AM

$MRNA V940 news coming

0 · Reply

PivotPoint_101 Jul. 4 at 2:44 AM

$IWM $MRNA 🎁💪 $QQQ $SPY

0 · Reply

BillyMcMc Jul. 3 at 7:31 PM

$MRNX too bad i didnt hold fml $MRNA

0 · Reply

WAJeff Jul. 3 at 6:33 PM

#51-75 realized gainer changes: NXT to #51. $MRNA (169.59% ytd) rose to #56, $COHU (148.12% ytd) rose to #64 after a bunch sold at $74, $VRTX (16.21% ytd, this was a long hold for me and I likely sold way too early) is new at #71, $DCO (96.15% ytd) rose to #75.

0 · Reply

NicaInvest85 Jul. 3 at 5:41 PM

$CRBU $MRNA IS KILLING IT

0 · Reply

IndyOne Jul. 3 at 5:24 PM

$MRNA CANCER FRANCHISE: Moderna's mRNA‑4157/V940 cancer vaccines have: ***Randomized Phase 2b data showing 49% reduction in recurrence/death vs Keytruda alone. Merck is partner. ***Multiple Phase 3 trials underway, reporting results this year. ***Here's the massive tell from Moderna. I have tracked their hiring patterns. Massive hiring for oncology, including senior leaders. No company on the planet draws new executives on board without the receipts. Moderna already knows and we will soon. V940. Yeah, Baby, Yeah!!!

2 · Reply

PivotPoint_101 Jul. 3 at 5:15 PM

$SPY $QQQ $JNJ #pivotgroup🎬🎁 $MRNA 🔐🏦 Sold the 9/18 Held the 1/15 for dip add+ $100 Later

0 · Reply

Biotechlineup Jul. 3 at 5:02 PM

$MRNA Neoatigens will fail commercially Matrix-M would act as a massive structural accelerator for Moderna’s mRNA-4359, transforming it from a localized treatment into a relentless, systemic hunt for metastatic cancer.While mRNA-4359 provides the blueprint to defeat tumor cloaking, Matrix-M provides the physical infrastructure to manufacture the army required to carry out that order.Pairing the two creates an optimized, three-part synergy. The Cross-presentation. PD-L1 and IDO1.The Normal Bottleneck:, When Moderna's lipid nanoparticles deliver this mRNA into an immune cell (like a dendritic cell), the cell creates the target proteins, but they often get trapped inside internal cellular waste bins called lysosomes. This results in a weak, helper immune response (CD4+ T-cells).The Matrix-M Upgrade, Matrix-M physically induces Lysosomal Membrane Permeabilization (LMP). It forces those lysosomes to open up, letting the mRNA-generated cancer targets escape directly into the cell's fluid.

0 · Reply

trachea Jul. 3 at 3:44 PM

$MRNA well - Sounds Big!👍🍀💪

0 · Reply

IndyOne Jul. 3 at 2:55 PM

$MRNA DOUBLE TAP BREAKOUT BUY: mRNA‑4157 / V940 (intismeran autogene, personalized to each cancer patient) and mRNA‑4359 (mass market immuno‑oncology therapy) news coming . . . big

0 · Reply

Night_Owl_Biotech Jul. 3 at 2:36 PM

The $XBI is up 24.5% the last 15 trading sessions (since 6/10/2026). Investors may recall 4 years ago this time when the XBI surged 31.6% between 6/14/22 & 7/6/22. Excluding the market recovery during COVID in 2020, there's only 2 other times the XBI surged like this (15 day period ending 1/16/19 & before Thanksgiving back in 16). The XBI is almost at its record high. It traded at over $160 for 11 days back in early 2021 Recall it was May 12, 2026 when Dr. Makary resigned. Since then the FDA has reversed course on a number of bio's potential. Attached are the biggest gainers over the last 15 days (60% of more). $RGNX has overwhelmingly been the biggest winner now that they will refile for Navsunli approval in Q326. $SLS doubled again. Short interest is 36% per Seeking Alpha. At a $3B market cap SLS trades @ 4.3X Year 4 (FY30) revenue (from 1 analyst). We though we were smart when we sold SLS in the mid $4 range back in January. $DFTX reported its P3 win 6/22/26 $MRNA we have friends there :)

0 · Reply

free2dream Jul. 3 at 1:58 PM

$SRPT Sarepta should be your main pick prior earnings. The company valuation need to reprice - $200+ , should be valed same as $MRNA at $30B plus

0 · Reply

Bagga17654268 Jul. 3 at 10:00 AM

$MRNA where is my brand new baseboard?

0 · Reply

Market Cap	31.65B
Revenue (ttm)	1.94B
Net Income (ttm)	-2.82B
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-145.16%
Debt to Equity Ratio	0.08

Volume	14,111,900
Avg Vol	7,906,798
Day's Range	N/A - N/A
Shares Out	396.79M
Stochastic %K	93%
Beta	0.94
Analysts	Hold
Price Target	$47.86